Beijing Wantai Biological Pharmacy Enterprise Co Ltd Net Asset Quality Index
Beijing Wantai Biological Pharmacy Enterprise Co Ltd net asset quality index. Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has a Net Asset Quality Index of 86.8% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥13.71 Billion minus total liabilities of CN¥1.81 Billion yields net assets of CN¥11.90 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Beijing Wantai Biological Pharmacy Enter to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
Net asset quality index of Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025. This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the index stands at 86.8%, representing net assets of CN¥11.90 Billion against total assets of CN¥13.71 Billion CNY. See what is Beijing Wantai Biological Pharmacy Enter's book value for net asset value and shareholders' equity analysis.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Net Asset Quality Index by Year (2013–2025)
Beijing Wantai Biological Pharmacy Enterprise Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Beijing Wantai Biological Pharmacy Enter stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.7% | CN¥12.03 Billion | CN¥14.04 Billion | CN¥2.01 Billion | ▲ +0.9 pp |
| 2024 | 84.7% | CN¥12.45 Billion | CN¥14.69 Billion | CN¥2.24 Billion | ▲ +2.8 pp |
| 2023 | 82.0% | CN¥12.88 Billion | CN¥15.71 Billion | CN¥2.83 Billion | ▲ +4.6 pp |
| 2022 | 77.4% | CN¥12.56 Billion | CN¥16.23 Billion | CN¥3.66 Billion | ▲ +12.7 pp |
| 2021 | 64.8% | CN¥4.56 Billion | CN¥7.05 Billion | CN¥2.48 Billion | ▼ -8.9 pp |
| 2020 | 73.6% | CN¥2.58 Billion | CN¥3.50 Billion | CN¥923.29 Million | ▲ +0.6 pp |
| 2019 | 73.0% | CN¥1.58 Billion | CN¥2.16 Billion | CN¥584.19 Million | ▼ -2.5 pp |
| 2018 | 75.5% | CN¥1.37 Billion | CN¥1.81 Billion | CN¥444.24 Million | ▲ +21.2 pp |
| 2017 | 54.3% | CN¥898.99 Million | CN¥1.66 Billion | CN¥756.80 Million | ▼ -11.7 pp |
| 2016 | 66.0% | CN¥959.70 Million | CN¥1.45 Billion | CN¥494.76 Million | ▲ +0.4 pp |
| 2015 | 65.6% | CN¥722.69 Million | CN¥1.10 Billion | CN¥378.93 Million | ▼ -6.4 pp |
| 2014 | 72.0% | CN¥580.32 Million | CN¥805.50 Million | CN¥225.19 Million | ▲ +9.1 pp |
| 2013 | 62.9% | CN¥382.06 Million | CN¥606.98 Million | CN¥224.92 Million | — |